コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 iated inflammatory mediators (in particular, monocyte chemoattractant protein-1).
2 nhibitor-1, and C-C motif chemokine ligand 2/monocyte chemoattractant protein 1.
3 eta), tumor necrosis factor (TNF), IL-6, and monocyte chemoattractant protein 1.
4 ression of proinflammatory interleukin 6 and monocyte chemoattractant protein 1.
5 ed levels of tumor necrosis factor alpha and monocyte chemoattractant protein 1.
6 nitric oxide synthase 3, thrombomodulin, and monocyte chemoattractant protein-1.
7 ming systemic inflammation was the chemokine monocyte chemoattractant protein-1.
8 their migration in response to the chemokine monocyte chemoattractant protein-1.
9 stemic interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1.
10 nd secretion of the proinflammatory cytokine monocyte chemoattractant protein-1.
11 th-regulated oncogene-alpha (GRO-alpha), and monocyte chemoattractant protein-1.
12 splanted visceral fat pad and reduced plasma monocyte chemoattractant protein-1.
13 cated in endogenous fat inflammation such as monocyte chemoattractant protein-1.
14 necrosis factor-beta, interferon-gamma, and monocyte chemoattractant protein-1.
15 f intercellular cell adhesion molecule-1 and monocyte chemoattractant protein-1.
16 a-like ligand 4, apelin, angiopoietin-2, and monocyte chemoattractant protein-1.
17 5%, P < 0.002; interleukin-6, 13%, P < 0.01; monocyte chemoattractant protein-1, 10%, P < 0.0006) and
18 or necrosis factor-alpha (-16% versus +12%), monocyte chemoattractant protein-1 (-13% versus +0.2%),
19 creases in interleukin-6 (21%; P < 0.02) and monocyte chemoattractant protein 1 (14% decrease at 4 wk
20 ange messenger RNA: interleukin-1beta = 7.6, monocyte chemoattractant protein-1 = 15.3, and tumor nec
21 ations of inflammatory biomarkers, including monocyte chemoattractant protein-1 (adjusted OR 9.0 [95%
22 ls of IL-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 after stimulation wit
23 increased CD68, tumor necrosis factor alpha, monocyte chemoattractant protein-1, alpha-smooth muscle
24 remote myocardium (e.g., 12-fold increase of monocyte chemoattractant protein-1), although levels wer
25 increases in CC chemokine ligand 2 (CCL2, or monocyte chemoattractant protein-1), an important macrop
27 diponectin and leptin while reducing that of monocyte chemoattractant protein 1 and interleukin-8 by
28 eotaxin, IL-2, and IL-12 and the chemokines monocyte chemoattractant protein 1 and keratinocyte-deri
29 alveolar epithelial cells produced excessive monocyte chemoattractant protein 1 and reactive oxygen s
32 ion correlated with decreased levels of MCP (monocyte chemoattractant protein)-1 and IL (interleukin)
33 n the vascular wall (decreased production of monocyte chemoattractant protein-1 and activation of p38
35 ukin-6, tumor necrosis factor) and adaptive (monocyte chemoattractant protein-1 and CXCL10 chemokines
36 plasia and pro-inflammatory gene expression (monocyte chemoattractant protein-1 and cytokine-induced
37 or necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1 and decreased M2 mark
38 ry and proproliferative mediators, including monocyte chemoattractant protein-1 and hypoxia-inducible
39 Seeded BMCs secreted significant amounts of monocyte chemoattractant protein-1 and increased early m
40 d at the promoters of the inflammatory genes monocyte chemoattractant protein-1 and interleukin-6 in
41 in significantly reduced production of serum monocyte chemoattractant protein-1 and interleukin-6 lev
42 lial selectin surface expression and reduced monocyte chemoattractant protein-1 and interleukin-6 pro
43 sumption by inflammatory monocytes and serum monocyte chemoattractant protein-1 and interleukin-6 wer
44 -infected MSKO mouse livers had: (1) greater monocyte chemoattractant protein-1 and macrophage inflam
46 ased expression of the proinflammatory gene, monocyte chemoattractant protein-1 and matrix metallopro
47 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 and reduced mRNA and
48 25(OH)(2)D(3) supplementation also inhibited monocyte chemoattractant protein-1 and stimulated adipon
49 macrophages showed reduced migration toward monocyte chemoattractant protein-1 and transmigration th
50 uction of key proatherogenic factors such as monocyte chemoattractant protein-1 and tumor necrosis fa
52 oliferating cell nuclear antigen+ cells, and monocyte chemoattractant protein-1 and vascular cell adh
53 okine (C-C motif) ligand 5 and expression of monocyte chemoattractant protein-1 and vascular cell adh
54 sAPPbeta) and two neuroinflammatory markers (monocyte chemoattractant protein-1 and YKL-40) were meas
55 ion of chemokine (C-C motif) ligand (CCL) 2 (monocyte chemoattractant protein 1) and CCL3 (macrophage
56 he TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattractant protein-1) and GM-CSF genes, an
57 ed with increased renal expression of MCP-1 (monocyte chemoattractant protein-1) and VLA-4 (very-late
58 necrosis factor alpha, interleukin-6, CCL2 (monocyte chemoattractant protein 1), and CCL5 (RANTES).
59 F-beta, connective tissue growth factor, and monocyte chemoattractant protein 1), and epithelial-to-m
60 induced inflammation (tumor necrosis factor, monocyte chemoattractant protein 1, and chemokine [C-X-C
61 s of myeloperoxidase, tumor necrosis factor, monocyte chemoattractant protein 1, and gamma interferon
62 eukin 1beta (IL-1beta), IL-6, CXCL1/KC, CCL2/monocyte chemoattractant protein 1, and granulocyte colo
63 terleukin-6, keratinocyte-derived chemokine, monocyte chemoattractant protein 1, and interleukin-10),
64 e, with extremely high mRNA levels for IL-8, monocyte chemoattractant protein 1, and macrophage infla
65 asminogen activator receptor, interleukin-6, monocyte chemoattractant protein 1, and matrix metallopr
66 ene and protein expression of tissue factor, monocyte chemoattractant protein-1, and cyclooxygenase-2
67 ated lipocalin, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and fractional hypox
68 on- gamma , interleukin [IL]-4, IL-10, IL-6, monocyte chemoattractant protein-1, and growth-regulated
69 with statistically different levels of IL-6, monocyte chemoattractant protein-1, and heat-shock prote
70 ed secretion of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and interleukin-12.
71 lecule-1, intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and interleukin-17A;
72 increased expression of inflammatory genes, monocyte chemoattractant protein-1, and interleukin-6, a
73 irculating levels of P-selectin, E-selectin, monocyte chemoattractant protein-1, and macrophage conte
74 lating factor, keratinocyte chemoattractant, monocyte chemoattractant protein-1, and macrophage infla
75 atory cytokines tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and macrophage infla
76 ative stress, expression of endothelin-1 and monocyte chemoattractant protein-1, and monocyte homing.
77 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f
78 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f
79 L-8, IL-10, interferon-inducible protein-10, monocyte chemoattractant protein-1, and tumor necrosis f
80 roinflammatory cytokines (interleukin-1beta, monocyte chemoattractant protein-1, and tumor necrosis f
81 ession of intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and vascular endothe
82 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 as 129/B6-ApoE(-/-) c
83 ficantly with matrix metalloproteinase-3 and monocyte chemoattractant protein-1 at baseline, biomarke
84 iR-132 and demonstrated that miR-132 induces monocyte chemoattractant protein-1 at least in part via
85 ellular protease plasmin cleaves mouse MCP1 (monocyte chemoattractant protein 1) at lysine 104, relea
86 m levels of CD40 ligand, serum amyloid A and monocyte chemoattractant protein-1, (b) limited evidence
87 from WKY rats synthesized significantly more monocyte chemoattractant protein-1 basally and after sti
88 mL; low-BCAA: 5.7 +/- 1 pg/mL; P = 0.01) and monocyte chemoattractant protein-1 (BCAA: -0.4% +/- 9%;
89 7/BL6 mice, markedly augmented the levels of monocyte chemoattractant protein-1 bound to RBCs, which
90 of tumor necrosis factor, interleukin-6, and monocyte chemoattractant protein 1 by spleen cells was a
91 osis factor-alpha, IL-1beta, IL-6, IL-8, and monocyte chemoattractant protein-1 by co-cultured dendri
92 IL-8, granulocyte colony-stimulating factor, monocyte chemoattractant protein-1, C-reactive protein,
93 Importantly, our data demonstrate that the monocyte chemoattractant protein-1/C-C chemokine recepto
94 ssive neuroblastoma, repressed expression of monocyte chemoattractant protein-1/CC chemokine ligand 2
95 terferon [IFN-gamma], and IL-6), chemokines (monocyte chemoattractant protein 1/CCL-2, macrophage inf
97 ll alpha chemoattractant (I-TAC/CXCL11), and monocyte chemoattractant protein 1 (CCL2) were measured
98 CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinic
99 d PGE(2)-induced production of the chemokine monocyte chemoattractant protein-1 (CCL2), which was lin
100 an IC50 of 22.8 nM but was inactive against monocyte chemoattractant protein-1 (CCL2)-mediated calci
101 of histamine, cytokines, and the chemokines monocyte chemoattractant protein 1/CCL2, macrophage infl
102 n stimulation with CXCL16 astrocytes release monocyte chemoattractant protein-1/CCL2 and (2) the neur
104 crosis factor-alpha) and chemokines (such as monocyte chemoattractant protein-1/ chemokine (C-C motif
105 biomarkers (glial fibrillary acidic protein, monocyte chemoattractant protein 1/chemokine (C-C motif)
106 glial fibrillary acidic protein (p = 0.002), monocyte chemoattractant protein 1/chemokine (C-C motif)
107 leukin-8/C-X-C motif chemokine ligand 8, and monocyte chemoattractant protein-1/chemokine ligand 2 in
108 8/C-X-C motif chemokine ligand 8 P=0.04, and monocyte chemoattractant protein-1/chemokine ligand 2 P=
109 ts contained increased leptin, resistin, and monocyte chemoattractant protein-1 compared with plasma
110 12p40, interferon-inducible protein 10, and monocyte chemoattractant protein 1 concentrations, where
112 growth factor, hepatocyte growth factor and monocyte chemoattractant protein-1, contributing to deve
113 enes such as tumor necrosis factor-alpha and monocyte chemoattractant protein-1, decreased AT inflamm
114 ased mRNA and immunostaining of IL-1beta and monocyte chemoattractant protein-1, decreased mRNA of in
115 of THP-1 monocytes to migrate toward MCP-1 (monocyte chemoattractant protein 1) depended upon Par3 a
116 nside-out activation of beta(2) integrins by monocyte chemoattractant protein-1 did not change IL-13-
118 y reduced hepatic inflammation, particularly monocyte chemoattractant protein-1 expression and macrop
119 ell as vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression in endothe
120 n, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 expression induced by
124 proinflammatory mediators interleukin-6 and monocyte chemoattractant protein-1, fibroblast growth fa
125 nterferon gamma-inducible protein of 10 kDa, monocyte chemoattractant protein 1, growth-related oncog
126 binding oligomerization domain containing-2, monocyte chemoattractant protein-1, IL-2, and IL-12p40 i
127 micked by stimulation of Hmox1(+/+) SCs with monocyte chemoattractant protein-1, IL-6, IL-1beta, and
128 tate dehydrogenase, as well as expression of monocyte chemoattractant protein-1, IL-6, IL-1beta, and
129 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein 1 in lumbar spinal cord
130 hyper-IgE syndrome generated lower levels of monocyte chemoattractant protein 1 in response to the pr
131 on of interleukin 1beta, interleukin 10, and monocyte chemoattractant protein 1 in response to ZIKV,
132 n, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 in a mouse model of o
133 tic lesion areas and decreased expression of monocyte chemoattractant protein-1 in the aorta as compa
135 elian randomization suggest a role of MCP-1 (monocyte chemoattractant protein-1) in atherosclerosis a
136 ntercellular adhesion molecule-1], and MCP1 [monocyte chemoattractant protein 1]), increases inflamma
139 accumulation, apoptosis, necrotic cores, and monocyte chemoattractant protein 1, interleukin 1beta, i
140 inflammatory response through alteration of monocyte chemoattractant protein-1, interleukin-1beta, a
141 of cytokines keratinocyte-derived chemokine, monocyte chemoattractant protein-1, interleukin-6 (IL-6)
142 m TK-/- mice exhibited blunted production of monocyte chemoattractant protein-1, interleukin-6, and m
143 oduction of cytokines and chemokines, namely monocyte chemoattractant protein-1, interleukin-6, and m
144 icantly higher levels of expression of cKIT, monocyte chemoattractant protein-1, interleukin-6, strom
145 ion, as denoted by the reduced expression of monocyte chemoattractant protein-1, intracellular adhesi
146 cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1, is markedly increase
147 ial protein expression of interleukin-18 and monocyte chemoattractant protein-1, key mediators of car
148 ction was strongly correlated with increased monocyte chemoattractant protein 1 levels (r = 0.396, P
149 eased plasma tumor necrosis factor-alpha and monocyte chemoattractant protein-1 levels in Tg-hCBS apo
150 igation and puncture, and interleukin 10 and monocyte chemoattractant protein-1 levels were higher in
153 ing factor were significantly reduced, while monocyte chemoattractant protein 1, macrophage inflammat
154 ngII-induced expression of cyclooxygenase-2, monocyte chemoattractant protein-1, macrophage inflammat
155 protein-1alpha, and C-reactive protein, and monocyte chemoattractant protein-1, macrophage inflammat
157 terferon-gamma inducible protein-10 [IP-10], monocyte chemoattractant protein-1, macrophage inflammat
158 ing tumor necrosis factor alpha (TNF-alpha); monocyte chemoattractant protein 1; macrophage inflammat
159 heal had higher tumor necrosis factor-alpha, monocyte chemoattractant protein-1, matrix metallopeptid
160 ssion of the fibrocyte recruiting chemokines monocyte chemoattractant protein 1 (MCP-1) and CXCL12, a
161 ed, there was a significant decrease in CCL2/monocyte chemoattractant protein 1 (MCP-1) and inflammat
162 stability of tumor necrosis factor alpha and monocyte chemoattractant protein 1 (MCP-1) but strongly
163 low-density lipoprotein (ox-LDL)-stimulated monocyte chemoattractant protein 1 (MCP-1) from macropha
164 d various levels of interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t
165 lammatory cytokines interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t
166 ssion of the inflammatory mediators CD36 and monocyte chemoattractant protein 1 (MCP-1) in the brain
174 ar adhesion molecule 1 (ICAM-1), E-selectin, monocyte chemoattractant protein 1 (MCP-1), and interleu
175 ndent secretion of CRS biomarkers, including monocyte chemoattractant protein 1 (MCP-1), interleukin
177 ter infection (day 2), interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP-1), macrophage i
178 anulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant protein 1 (MCP-1), macrophage i
179 s of IFN-gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage i
180 IL-12, and IL-18; chemokines, such as IL-8, monocyte chemoattractant protein 1 (MCP-1), RANTES, and
181 rogenase, and inflammatory mediators such as monocyte chemoattractant protein 1 (MCP-1), TNF-alpha, a
186 , we show that T. cruzi strongly upregulates monocyte chemoattractant protein 1 (MCP-1)/CCL2 and frac
187 l-derived factor 1alpha (SDF-1alpha)/CXCL12, monocyte chemoattractant protein 1 (MCP-1)/CCL2, and vas
189 , S1P stimulated secretion of the chemokine, monocyte chemoattractant protein 1 (MCP-1/CCL2), from th
190 ctants were induced in the kidney, including monocyte chemoattractant protein 1 (MCP-1/CCL2), macroph
191 5), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.0
192 ion, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower
193 6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and C-reactiv
195 ited TNF-alpha-induced inflammatory factors, monocyte chemoattractant protein-1 (MCP-1) and interleuk
196 so increased levels of inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1) and MCP-1 ind
197 ble cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak inte
198 h as interleukin (IL)-6, IL-1beta, IL-8, and monocyte chemoattractant protein-1 (MCP-1) and the secre
199 d and is accompanied by increases in mRNA of monocyte chemoattractant protein-1 (MCP-1) and tumor nec
200 VSMC stimulated by TGF-beta/AdSmad3 revealed monocyte chemoattractant protein-1 (MCP-1) as a likely f
201 pirfenidone impaired macrophage migration to monocyte chemoattractant protein-1 (MCP-1) as well as IL
202 lls, which directly stimulates expression of monocyte chemoattractant protein-1 (Mcp-1) by macrophage
203 an obligate dimeric mutant of the chemokine monocyte chemoattractant protein-1 (MCP-1) by substituti
205 uced Src and STAT3 tyrosine phosphorylation, monocyte chemoattractant protein-1 (MCP-1) expression an
206 JNK as the exclusive mediator of FFA-induced monocyte chemoattractant protein-1 (MCP-1) expression in
209 atment with p38 MAPK inhibitor reduced renal monocyte chemoattractant protein-1 (MCP-1) levels, the n
210 a murine model of an arteriovenous fistula, monocyte chemoattractant protein-1 (MCP-1) mRNA and prot
211 chemokine receptor 2 (CCR2) with its ligand, monocyte chemoattractant protein-1 (MCP-1) promotes canc
215 mobility mass spectrometry (IMMS) to analyze monocyte chemoattractant protein-1 (MCP-1), a CC chemoki
217 in HK-2 cells to stimulate the production of monocyte chemoattractant protein-1 (MCP-1), a key chemok
218 -1beta (IL-1beta), the cytokines IL-8, IL-6, monocyte chemoattractant protein-1 (MCP-1), and growth-r
219 yperactivation of ERK and p38 in response to monocyte chemoattractant protein-1 (MCP-1), and increase
220 phage accumulation, diminished expression of monocyte chemoattractant protein-1 (MCP-1), and lower le
221 activation-regulated chemokine (TARC), IL-8, monocyte chemoattractant protein-1 (MCP-1), and murine b
222 Stroke outcome, expression of brain CD36, monocyte chemoattractant protein-1 (MCP-1), CCR2, and pl
224 n (IFN)-gamma- inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), IFN-gamma, i
226 d beta2-integrins, cyclooxygenase-2 (COX-2), monocyte chemoattractant protein-1 (MCP-1), interleukin-
227 We have previously shown that the chemokine, monocyte chemoattractant protein-1 (MCP-1), is a mediato
229 ge inflammatory protein-1alpha (MIP-1alpha), monocyte chemoattractant protein-1 (MCP-1), regulated on
230 n-gamma-inducible protein of 10 kDa (IP-10), monocyte chemoattractant protein-1 (MCP-1), tumor necros
231 netic basis of circulating concentrations of monocyte chemoattractant protein-1 (MCP-1), we conducted
238 chemotaxis can be signaled by the chemokine monocyte chemoattractant protein-1 (MCP-1)/CCL2 (CC chem
239 that interact with the oligomeric chemokine Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2 with dif
240 rated increased expression of iNOS, C1r, and monocyte chemoattractant protein-1 (MCP-1); MCP-1 expres
241 RK) to mechanically trigger the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as
242 ort the expression profile of the chemokine, monocyte chemoattractant protein-1 (MCP-1, CCL2), during
244 to chronic pain includes the upregulation of monocyte chemoattractant protein-1 (MCP-1/CCL2) and its
245 proinflammatory cytokine IL-6 and chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) in respo
246 keratinocytes up-regulated the expression of monocyte chemoattractant protein-1 (MCP-1/CCL2), TNFalph
248 ta, IL-23, interferon (IFN)-beta, IFN-gamma, monocyte chemoattractant protein 1 [MCP-1; chemokine (C-
249 mor necrosis factor alpha (TNF-alpha), CCL2 (monocyte chemoattractant protein 1 [MCP-1]), and CCL5 (R
251 ines (interleukin 6 [IL-6], IL-8, IL-1alpha, monocyte chemoattractant protein 1 [MCP-1], and colony-s
252 atory cytokines (interleukin-6 [IL-6], IL-8, monocyte chemoattractant protein 1 [MCP-1], and IL-1beta
253 we show that TXA(2) mimetic, I-BOP, induced monocyte chemoattractant protein -1(MCP-1)/chemokine (C-
254 ce was observed, certain chemokines (RANTES, monocyte chemoattractant protein 1[MCP-1], and IP-10) we
255 eoprotegerin (OPG) expression and increasing monocyte chemoattractant protein 1 (MCP1) expression in
256 rleukin-6 (Il-6), interleukin-1beta (Il-1b), monocyte chemoattractant protein 1 (Mcp1), and fibrosis-
257 ic pain, and mice overexpressing its ligand, monocyte chemoattractant protein-1 (MCP1; also known as
258 ential of mouse melanoma cells in HDAC3- and monocyte chemoattractant protein 1-(MCP1)-dependent mann
259 CI and other wild type CC chemokines, MCP-1 (monocyte chemoattractant protein-1), MIP-1beta, and RANT
260 10]), and proinflammatory cytokines (MCP-1 [monocyte chemoattractant protein 1], MIP-1alpha/beta [ma
261 essed and secreted, T-cell activation-3, and monocyte chemoattractant protein-1 mRNAs were lower comp
263 , TNF-alpha (P = .006), IL-1beta (P = .022), monocyte chemoattractant protein 1 (P = .028), RANTES (P
264 kin-6 (P=0.01), isoprostanes (P=0.0002), and monocyte chemoattractant protein-1 (P=0.008); SAT only r
265 proteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant protein-1, P-selectin, fibrinog
266 ric inhibitory polypeptide, insulin, leptin, monocyte chemoattractant protein-1, pancreatic polypepti
267 Expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, plasminogen activato
268 e (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, plays a critical rol
269 educed IL-4, IL-5, IL-13, eotaxin, IL-8, and monocyte chemoattractant protein 1 production without af
270 found a 3-fold increase in interleukin-6 and monocyte chemoattractant protein-1 production by G2A(-/-
271 Pio also did not attenuate Ang II-induced monocyte chemoattractant protein-1 production in PPARgam
272 responses to TLR2 and TLR4 ligands, reduced monocyte chemoattractant protein-1 production, and preve
273 ammation, limits neutrophils recruitment and monocyte chemoattractant protein-1 production, thus redu
275 cts of Klotho signaling on interleukin-8 and monocyte chemoattractant protein-1 promoter recruitment
277 isoprostanes, R2 0.07 versus 0.10, P=0.002; monocyte chemoattractant protein-1, R2 0.07 versus 0.08,
278 sis included higher levels of interleukin-8, monocyte chemoattractant protein-1, resistin, soluble in
279 Given its unique role, future studies into monocyte chemoattractant protein-1's exact role during s
280 hly associated with urinary isoprostanes and monocyte chemoattractant protein-1 (SAT versus VAT compa
281 sociated phospholipase A2 mass and activity, monocyte chemoattractant protein-1, soluble endothelial
282 methylarginine, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, soluble vascular cel
283 toreceptor cultures exposed to starvation or monocyte chemoattractant protein-1-stimulated (MCP-1-sti
284 rleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein 1), suggesting that mes
285 reduced astrogliosis, interleukin-1beta, and monocyte chemoattractant protein-1, suggesting a paracri
286 yed similar up-regulation of miR-132/212 and monocyte chemoattractant protein-1, supporting in vivo r
287 This was associated with marked increase in monocyte chemoattractant protein-1 synthesis in WKY glom
288 emokine, C-C motif chemokine ligand 2 (CCL2; monocyte chemoattractant protein 1), termed mNOX-E36, in
289 erestingly, higher levels of interleukin 22, monocyte chemoattractant protein 1, TNF-alpha, and IP-10
290 in systolic BP, heart rate variability, and monocyte chemoattractant protein-1, together with reduce
291 sion of proinflammatory cytokines (including monocyte chemoattractant protein 1, tumor necrosis facto
292 mug/mL significantly decreased production of monocyte chemoattractant protein-1, tumor necrosis facto
293 nes for interleukin (IL)-1beta, IL-6, IL-10, monocyte chemoattractant protein-1, tumor necrosis facto
295 ray indicated that the chemokine CCL2/MCP-1 (monocyte chemoattractant protein-1) was strongly induced
296 ), monokine induced by interferon-gamma, and monocyte chemoattractant protein 1 were quantified as me
297 , intercellular cell adhesion molecule-1 and monocyte chemoattractant protein-1, were also determined
298 idenced by the upregulation of ephrin B2 and monocyte chemoattractant protein-1, which are 2 stretch-
299 oprotein 1 stimulates macrophages to secrete monocyte chemoattractant protein-1, which then activates
300 nd decreased production of oxidant-inducible monocyte chemoattractant protein-1, which we have previo